Cure8 news brief
Patients with upper GI Crohn’s often have a more aggressive course; this registry analysis suggests they usually respond to biologic drugs similarly to other patients but still carry a higher long-term chance of needing intestinal surgery.
Adults with Crohn’s disease (especially those with upper GI/L4 involvement), clinicians managing biologic therapy, and researchers studying prognostic phenotypes and treatment outcomes.
The study used the ENEIDA registry (2015–2025) and measured treatment persistence (time to discontinuation for primary nonresponse or loss of response) and time to intestinal resection. After statistical weighting and adjustment, UGI (L4) was not associated with a meaningful decrease in biologic durability (HR ~1.03).
However, UGI—especially combined L4a+L4b—was associated with higher surgery risk (HR ~1.19 overall; ~1.47 for combined L4a+L4b). The analysis noted differences by biologic class: ustekinumab had greater persistence and lower resection risk in the cohort, but there was no clear interaction between biologic class and UGI phenotype.
These results suggest L4 may mark patients at higher surgical risk rather than indicating intrinsic biologic resistance.
Findings come from a retrospective analysis of the ENEIDA registry presented at UEG Week 2026. Registry and abstract-based results are hypothesis-generating and do not establish causation; details on confounders, definitions, and statistical models are limited in the conference abstract.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
This study suggests that regional differences in how often and how early advanced drugs are used didn’t change 10-year rates of surgery, hospitalization, or progression to complicated Crohn’s disease in this cohort.
A genetic marker (HLA-DRB1*01:03) was linked to more severe IBD outcomes—higher rates of colectomy/colonic surgery, more perianal disease, earlier use and higher failure of advanced therapies—which could help explain...
The findings suggest that over three decades more patients receive medical prevention after ileocolic resection — including thiopurines and biologics — and that rates of needing a second surgery have fallen. This matters...
